| Drug Name |
Telbivudine |
| Drug ID |
BADD_D02145 |
| Description |
Telbivudine is a synthetic thymidine nucleoside analog with specific activity against the hepatitis B virus. Telbivudine is orally administered, with good tolerance, lack of toxicity and no dose-limiting side effects. |
| Indications and Usage |
For the treatment of chronic hepatitis B in adult and adolescent patients ≥16 years of age with evidence of viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease. |
| Marketing Status |
approved; investigational |
| ATC Code |
J05AF11 |
| DrugBank ID |
DB01265
|
| KEGG ID |
D06675
|
| MeSH ID |
D000077712
|
| PubChem ID |
159269
|
| TTD Drug ID |
D0CL9S
|
| NDC Product Code |
Not Available |
| UNII |
2OC4HKD3SF
|
| Synonyms |
Telbivudine | 1-(2-Deoxy-beta-L-erythropentafuranosyl)-5-methyl-2,4(1H,3H)-pyrimidinedione | beta-L-2'-Deoxythymidine | beta L 2' Deoxythymidine | Telbivudin | Tyzeka |
